ClinicalTrials.gg
CompletedNCT06441656Flip and FixUpdated Jun 4, 2024

The (Flip and Fix) Internal Limiting Flap Technique Versus the Classic Temporal Flap for Macular Hole Repair

An interventional study of Vitrectomy with ILM flap in Hacular Hole Repair, sponsored by Alexandria University. Completed at 1 site in Egypt. Open to participants aged 50 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by Alexandria University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Feb 2021, registered May 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
50 Years to 100 Years
Sex
All
01

Study summary

Purpose To describe a novel technique of MH repair and compare it to the perfluorocarbon liquid (PFCL) assisted temporal ILM flap technique.

Methods Twenty-two eyes of 22 patients with MH were randomized on 1:1 basis into two groups. Group A cases were treated using the (Flip and Fix) technique in which the single-layer ILM flap was (flipped), flattened over the macula using PFCL and (fixed) in place using 2 drops of autologous non-heparinized blood over the superonasal and the inferonasal edges of the flap (away from the MH center). Group B patients had the classic temporal ILM flap technique without using the PFCL or autologous blood. All patients were followed up for a period of 6 months after the surgery.

Results No significant difference was observed in initial and final visual acuities between Groups A and B. Intraoperative flap displacement and did not occur in Group A and occurred in 2 eyes in Group B (18.2%) one of them showed failed MH closure and required reoperation, These 2 cases had a final (W shape) MH closure and a worse final vision than the remaining cases which had either (U shape) or (V shape) final MH closure.

Conclusions The study results show that the (Flip and Fix) technique is as effective as the PFCL-assisted temporal ILM flap technique and is associated with less ILM flap displacement risk for the repair of macular holes.

Read the detailed description

We conducted a prospective randomized comparative interventional study in which we enrolled patients older than 50 years with idiopathic macular holes who presented to (Removed in the blinded version of manuscript) in the period between February 2021 and February 2022. Patients with previous macular surgeries and those with any other significant macular pathologies e.g., diabetic macular oedema, myopic maculopathy, choroidal neovascular membrane, or macula-off retinal detachment were excluded.

The study protocol was reviewed and approved by the Ethics Committee of (Removed in the blinded version of manuscript). All patients signed an informed consent after explaining the procedures. The study was conducted in accordance with the tenets of the Declaration of Helsinki.

For all the patients, a retina consultant (I. A.) masked to the procedure that will be done for the patient conducted a comprehensive ophthalmic examination, including best-corrected visual acuity (BCVA) (measured using the Snellen's chart and then converted to the LogMAR for the statistical analysis), slit-lamp examination, and fundus examination.

All the patients had a pre-operative macular OCT scan done. The scans were assessed by the masked retina consultant (I. A.) to confirm the diagnosis and to measure the minimum MH diameter.

The included patients were randomized by a research nurse on a 1:1 basis using the closed envelope technique to have either the new (Flip and fix) technique (Group A) or the PFCL assisted temporal inverted ILM flap technique (Group B).

All the surgeries were done under general anaesthesia by a single surgeon (M. A.) using a wide-angle viewing non-contact system (Resight; Carl Zeiss Meditec AG, Jena, Germany) and 23 Gauge Alcon Constellation vitrectomy machine (Alcon Laboratories, Fort Worth, TX) to complete the core vitrectomy and induction of the posterior vitreous detachment if not already detached, this was followed by an injection the Brilliant Blue G (Tissueblue 0.025% DORC, Zuidland, The Netherland) to stain the ILM.

In both groups, a single-layer ILM temporal flap of approximately 2 times the size of the optic disc was fashioned using an ILM forceps temporal to the macula. The nasal edge of the flap was not detached from the temporal MH edge. The flap was reflected nasally to cover the MH In the (Flip and Fix) technique group, the (flipped) ILM flap was secured in place and flattened over the macular surface using a 1.5 cc bubble of PFCL (Arcaline; Arcadophtha, Toulouse, France) injected over the flipped ILM flap. Then fluid air exchange with removal of the PFCL bubble was done followed by (fixing) the ILM flap over the macular surface using two drops of autologous non-heparinized blood -collected by the attending nurse or anaesthesiologist from one of the veins on the dorsum of the hand- one dropped over the superior-nasal and another at the inferior-nasal edges of the ILM flap (away from the MH center). On the other hand, in the classic temporal ILM flap group, PFCL and blood were not used to fix the ILM flap. Videos demonstrating the technique are provided as supplemental files 1 and 2.

In both groups, at the conclusion of the surgery the air was exchanged for a non-expansile concentration (20%) of sulphur hexafluoride gas SF6 and the patient was asked to maintain a face -down position for 5 days postoperatively. The surgical steps of the (flap and fix) technique are summarized in Figure 1.

For all the cases, intraoperative ILM flap displacement (defined as a significant displacement of the inverted ILM flap after its initial positioning over the MH that necessitated readjustment) was reported by the operating surgeon.

All the patients were examined postoperatively at 1, 3, and 6 months by a retina consultant masked to the used surgical procedure (I. A). The best corrected visual acuity, slit-lamp examination, fundus examination and macular OCT scanning were done in each postoperative visit.

According to the cross-sectional morphology on the postoperative macular OCT scan, foveal contour was classified into one of the following categories: U-shape, V-shape, and W-shape (irregular). The presence of a thin hyperreflective band of tissue extending on both sides of the previous MH Flap between the inner surface of the retina was assessed and considered a (membranous i.e., flap closure).

The data about the pre-operative MH base size, minimum MH diameter, BCVA, post-operative closure rate, BCVA, and the pattern of the MH closure was collected.

02

Conditions studied

  • Hacular Hole Repair

Browse trials for

Keywords

  • Macular hole, Internal limiting membrane, pars plana vitrectomy, perfluorocarbon liquid, non-heparinized blood
03

In context

Retinal Perforations

139 studies on the registry are indexed under Retinal Perforations; 22 are open to participants now.

This study's enrollment of 22 is below the median of 50 across 94 interventional studies indexed under Retinal Perforations.

Browse Retinal Perforations studies →

Lead sponsor

Alexandria University is the lead sponsor of 604 studies on the registry; 140 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: patients with idiopathic macular holes who presented to (Removed in the blinded version of manuscript) in the period between February 2021 and February 2022.

Exclusion Criteria: Patients with previous macular surgeries and those with any other significant macular pathologies e.g., diabetic macular oedema, myopic maculopathy, choroidal neovascular membrane, or macula-off retinal detachment -

-

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Flip and fix ILM flap

    In the (Flip and Fix) technique group, the (flipped) ILM flap was secured in place and flattened over the macular surface using a 1.5 cc bubble of PFCL (Arcaline; Arcadophtha, Toulouse, France) injected over the flipped ILM flap. Then fluid air exchange with removal of the PFCL bubble was done followed by (fixing) the ILM flap over the macular surface using two drops of autologous non-heparinized blood -collected by the attending nurse or anaesthesiologist from one of the veins on the dorsum of the hand- one dropped over the superior-nasal and another at the inferior-nasal edges of the ILM flap (away from the MH center).

    Procedure: Vitrectomy with ILM flap

  • Active comparator
    classic temporal ILM flap

    PFCL and blood were not used to fix the ILM flap

    Procedure: Vitrectomy with ILM flap

Interventions

  • ProcedureVitrectomy with ILM flap

    In both groups, a single-layer ILM temporal flap of approximately 2 times the size of the optic disc was fashioned using an ILM forceps temporal to the macula. The nasal edge of the flap was not detached from the temporal MH edge. The flap was reflected nasally to cover the MH

06

What researchers measure

Primary outcomes

  1. Macular hoe closure by OCT scan

    Macular OCT scan was used to assess the MH closure

    Time frame: 1, 3, and six months postoperatively

  2. LogMAR visual acuity

    Best corrected visual acuity was assessed using the LogMAR vision

    Time frame: 1, 3, and six months postoperatively

07

Study locations

1 site
  • Faculty of Medicine Alexandria University
    Alexandria, Egypt
08

References and documents

Individual participant data

Plan to share: No — The data are available upon request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Feb 2022, 12 months.

Of 45 non-industry interventional studies with no phase under Retinal Perforations, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 12 months is below that.

Counting every sponsor, half of 45 studies reached it within 28 months; a quarter within 12 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 4, 2024
StartActual
Feb 1, 2021
Primary completionActual
Feb 1, 2022
CompletionActual
Feb 1, 2023
Last update
Jun 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06441656
Responsible party
Islam Shereen Hamdy (Associate Professor, Alexandria University) — Principal investigator
First posted
Jun 4, 2024
Start date
Feb 1, 2021
Primary completion
Feb 1, 2022
Completion
Feb 1, 2023
Last update
Jun 4, 2024

Study contacts

Islam SH Ahmed, M.D.
principal investigator · University of Alexandria

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion